Neutralizing Antibody Response to the AreXvy Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients: Assessment Against Reference and Seasonal Strains
Our findings demonstrate a sustained antibody response to the Arexvy<sup>®</sup> vaccine in a cohort of LTx recipients, with antibody titers sustained over six months. Further research is needed to assess the long-term durability of the immune response and the potential immunogenicity of this vaccine in LTx populations.
Authors
- Menucha Jurkowicz (ORCID: https://orcid.org/0009-0008-7167-384X)
- Tomer Hoffman (ORCID: https://orcid.org/0000-0003-3535-6835)
- Eyal Nachum
- Ofir Deri (ORCID: https://orcid.org/0000-0002-3357-1008)
- Dafna Yahav (ORCID: https://orcid.org/0000-0003-3181-9791)
- Yaniv Lustig (ORCID: https://orcid.org/0000-0001-7949-5912)
- Noam Matalon (ORCID: https://orcid.org/0000-0002-7257-9803)
- Yael Bezalel (ORCID: https://orcid.org/0000-0003-2964-4689)
- T. Sinai
- Liran Levy (ORCID: https://orcid.org/0000-0001-6368-8015)
- Michael Peled (ORCID: https://orcid.org/0000-0002-7567-577X)
- Milton Saute (ORCID: https://orcid.org/0000-0001-7381-4492)
- M. Benzimra
- Ital Nemet
- Michal Mandelboim (ORCID: https://orcid.org/0000-0002-5997-7241)
- Neta Shirin
Institutions
- Tel Aviv University (IL)
- Sheba Medical Center (IL)
- Israel Ministry of Health (IL)
Publication Details
- Journal
- Vaccines
- Published
- 2025-04-11
- DOI
- https://doi.org/10.3390/vaccines13040398
- Citations
- 3
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 4.06